为了探究胸腺肽α1联合阿德福韦酯对乙型肝炎的治疗作用,择取 2015 年2月-2016年12月我院收治的92例乙型肝炎患者作为研究对象,随机分为对照组和观察组,各46例.对照组采用阿德福韦酯治疗,观察组采用胸腺肽 α1+阿德福韦酯治疗,观察两组治疗48周后的临床疗效并监测不良反应情况.结果:观察组乙型肝炎患者治疗总有效率(93.47%,43/46)显著优于对照组(78.26%,36/46),组间差异具有统计学意义(P<0.05).观察组不良反应发生率(21.74%)与对照组比较(23.91%),无显著差异P>0.05,无统计学意义.结论:胸腺肽α1+阿德福韦酯方案用于乙型肝炎治疗临床疗效较好,抗乙型肝炎病毒效果显著提高且安全性较高,该治疗方案值得借鉴推广.%In order to investigate the therapeutic effect of thymosin α1 combined with adefovir dipivoxil on hepatitis B, 92 patients with hepatitis B treated in our hospital from February 2015 to December 2016 were randomly divided into control group and observation group, each for 46 cases.The control group was treated with adefovir dipivoxil.The observation group was treated with thymosin α1 combined with adefovir dipivoxil.The clinical efficacy of the two groups after 48 weeks was observed and the adverse reaction was observed.Results showed that the total effective rate of treatment group (93.47%, 43/46) was significantly better than that of the control group (78.26%, 36/46).The difference between the two groups was statistically significant (P<0.05).The incidence of adverse reactions in the observation group (21.74%) compared with the control group (23.91%) was no significant difference P>0.05.It concludes that thymosin α1 combined with adefovir dipivoxil is a safe and effective method for the treatment of hepatitis B, which is worthy of promotion.
展开▼
